FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3203184504> ?p ?o ?g. }

• W3203184504 abstract "Cervical cancer is the tenth diagnosed cancer in the world. Early-stage and locally recurrent disease may be cured with radical surgery or chemo-radiotherapy. However, if disease persists or recurs, options are limited and the prognosis is poor. In addition to chemotherapy, bevacizumab, an antiangiogenic agent, has recently demonstrated its efficacy in this setting. Cabozantinib is an oral small molecule tyrosine kinase inhibitor that exhibits potent inhibitory activity against several receptor tyrosine kinases that are known to influence tumor growth, metastasis, and angiogenesis. The main targets of Cabozantinib are VEGFR2, MET and AXL. It is currently approved for the treatment of metastatic renal cell carcinoma, hepatocellular carcinoma and medullary thyroid carcinoma. Given its angiogenic properties associated with growth factor receptors inhibition, Cabozantinib represents a potential active treatment in cervical carcinoma. In this context, we propose to assess the efficacy and safety of cabozantinib monotherapy in advanced/metastatic cervical carcinoma (CC) after failure to platinum-based regimen treatment.This study is a single-arm two-stage multicenter phase II aiming to simultaneously assess efficacy and safety of Cabozantinib among advanced/metastatic cervical carcinoma (CC) after failure to platinum-based regimen treatment. The main criterion will be based on both safety and clinical efficacy by conducting a Bryant-and-Day design. Safety endpoint is the proportion of patients with clinical gastro-intestinal (GI) perforation/fistula, GI-vaginal fistula and genito-urinary (GU) fistula events grade ≥ 2 (NCI CTCAE V.5.0) occurring up to one month after the end of treatment. Efficacy endpoint is the proportion of patients with disease control rate 3 months after Cabozantinib initiation. A patients' self-reported quality of life evaluation is also planned, as well as the investigation of nutritional outcomes. Cabozantinib will be administered at the daily dose of 60 mg given orally, without interruption until disease progression or discontinuation for any cause.Cabozantinib is a promising drug for patients with advanced/metastatic cervical cancer where few therapeutics options are available after failure to platinum-based regimen metastatic CC. It appears challenging to assess the interest of Cabozantinib in this indication, taking into account the potential toxicity of the drug.NCT04205799 , registered 2019 12 19.Version 3.1 dated from 2020 08 31." @default.
• W3203184504 created "2021-10-11" @default.
• W3203184504 creator A5016416039 @default.
• W3203184504 creator A5023854119 @default.
• W3203184504 creator A5026702908 @default.
• W3203184504 creator A5028829159 @default.
• W3203184504 creator A5031850292 @default.
• W3203184504 creator A5032307618 @default.
• W3203184504 creator A5040394407 @default.
• W3203184504 creator A5042461515 @default.
• W3203184504 creator A5057264839 @default.
• W3203184504 creator A5071243004 @default.
• W3203184504 creator A5071787067 @default.
• W3203184504 date "2021-09-25" @default.
• W3203184504 modified "2023-10-16" @default.
• W3203184504 title "CABOCOL-01 trial: a single-arm phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure" @default.
• W3203184504 cites W1932886553 @default.
• W3203184504 cites W1973753485 @default.
• W3203184504 cites W1980032822 @default.
• W3203184504 cites W2002786295 @default.
• W3203184504 cites W2006287686 @default.
• W3203184504 cites W2012980582 @default.
• W3203184504 cites W2015919139 @default.
• W3203184504 cites W2076264206 @default.
• W3203184504 cites W2086297427 @default.
• W3203184504 cites W2094337993 @default.
• W3203184504 cites W2100756525 @default.
• W3203184504 cites W2120113475 @default.
• W3203184504 cites W2126768246 @default.
• W3203184504 cites W2138550445 @default.
• W3203184504 cites W2139909466 @default.
• W3203184504 cites W2170781431 @default.
• W3203184504 cites W2170825221 @default.
• W3203184504 cites W2171725862 @default.
• W3203184504 cites W2301377106 @default.
• W3203184504 cites W2317483064 @default.
• W3203184504 cites W2415950182 @default.
• W3203184504 cites W2514283099 @default.
• W3203184504 cites W2560322684 @default.
• W3203184504 cites W2585631382 @default.
• W3203184504 cites W2735786620 @default.
• W3203184504 cites W2739116710 @default.
• W3203184504 cites W2742133220 @default.
• W3203184504 cites W2747777589 @default.
• W3203184504 cites W2754470378 @default.
• W3203184504 cites W2772794199 @default.
• W3203184504 cites W2783922191 @default.
• W3203184504 cites W2790729376 @default.
• W3203184504 cites W2890580441 @default.
• W3203184504 cites W2925815206 @default.
• W3203184504 cites W2964902343 @default.
• W3203184504 cites W3046984254 @default.
• W3203184504 cites W3047480083 @default.
• W3203184504 doi "https://doi.org/10.1186/s12885-021-08758-9" @default.
• W3203184504 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8465776" @default.
• W3203184504 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34563169" @default.
• W3203184504 hasPublicationYear "2021" @default.
• W3203184504 type Work @default.
• W3203184504 sameAs 3203184504 @default.
• W3203184504 citedByCount "1" @default.
• W3203184504 countsByYear W32031845042023 @default.
• W3203184504 crossrefType "journal-article" @default.
• W3203184504 hasAuthorship W3203184504A5016416039 @default.
• W3203184504 hasAuthorship W3203184504A5023854119 @default.
• W3203184504 hasAuthorship W3203184504A5026702908 @default.
• W3203184504 hasAuthorship W3203184504A5028829159 @default.
• W3203184504 hasAuthorship W3203184504A5031850292 @default.
• W3203184504 hasAuthorship W3203184504A5032307618 @default.
• W3203184504 hasAuthorship W3203184504A5040394407 @default.
• W3203184504 hasAuthorship W3203184504A5042461515 @default.
• W3203184504 hasAuthorship W3203184504A5057264839 @default.
• W3203184504 hasAuthorship W3203184504A5071243004 @default.
• W3203184504 hasAuthorship W3203184504A5071787067 @default.
• W3203184504 hasBestOaLocation W32031845041 @default.
• W3203184504 hasConcept C126322002 @default.
• W3203184504 hasConcept C141071460 @default.
• W3203184504 hasConcept C143998085 @default.
• W3203184504 hasConcept C203092338 @default.
• W3203184504 hasConcept C2777472916 @default.
• W3203184504 hasConcept C2779984678 @default.
• W3203184504 hasConcept C2781064419 @default.
• W3203184504 hasConcept C2781413609 @default.
• W3203184504 hasConcept C31760486 @default.
• W3203184504 hasConcept C535046627 @default.
• W3203184504 hasConcept C71924100 @default.
• W3203184504 hasConceptScore W3203184504C126322002 @default.
• W3203184504 hasConceptScore W3203184504C141071460 @default.
• W3203184504 hasConceptScore W3203184504C143998085 @default.
• W3203184504 hasConceptScore W3203184504C203092338 @default.
• W3203184504 hasConceptScore W3203184504C2777472916 @default.
• W3203184504 hasConceptScore W3203184504C2779984678 @default.
• W3203184504 hasConceptScore W3203184504C2781064419 @default.
• W3203184504 hasConceptScore W3203184504C2781413609 @default.
• W3203184504 hasConceptScore W3203184504C31760486 @default.
• W3203184504 hasConceptScore W3203184504C535046627 @default.
• W3203184504 hasConceptScore W3203184504C71924100 @default.
• W3203184504 hasIssue "1" @default.
• W3203184504 hasLocation W32031845041 @default.
• W3203184504 hasLocation W32031845042 @default.
• W3203184504 hasLocation W32031845043 @default.

• next